Cover Image
Market Research Report

ASIA PACIFIC BETA GLUCAN MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 636634
Published Content info 92 Pages
Delivery time: 1-2 business days
Price
Back to Top
ASIA PACIFIC BETA GLUCAN MARKET FORECAST 2018-2026
Published: May 14, 2018 Content info: 92 Pages
Description

KEY FINDINGS

The Asia-Pacific beta glucan market is expected to showcase a CAGR of 7.61% during the forecast period of 2018-2026. China dominated the beta glucan market in this region with a revenue of $xx million in 2017. The country is also expected to register the highest CAGR in the Asia-Pacific market over the forecast period.

MARKET INSIGHTS

The beta glucan market is segmented on the basis of end-users, category and sources. Apart from China, the other key markets in this region include India, Japan, Australia and South Korea. High disposable income, growing prevalence of cancer and increasing demand from the bakery industry are expected to drive the need for the Asia-Pacific beta-glucan market.

COMPETITIVE INSIGHTS

Some of the noted market players in this market are Chr. Hansen A/S, Koninklijke Dsm N.V, Kemin Industries, Alltech Biotechnology, Super Beta Glucan, Pharmacon Asa, Kerry Group Plc, Specialty Biotech Ltd, Milliporesigma (Merck), Cargill Inc, Tate & Lyle Plc, Garuda International Inc and Frutarom.

Table of Contents
Product Code: 17073

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. PHARMACEUTICAL- MAJOR MARKET BY END-USER
    • 3.2.2. SOLUBLE BETA GLUCAN HELD MAJOR CHUNK OF THE MARKET BY CATEGORY
    • 3.2.3. CEREALS TO OFFER LUCRATIVE OPPORTUNITIES

4. MARKET DYNAMICS

  • 4.1. MARKET DEFINITION
  • 4.2. DRIVERS
    • 4.2.1. GROWING HEALTH CONCERN AMONG CONSUMERS AND INCREASING HEALTH EXPENDITURE
    • 4.2.2. GROWING APPLICATIONS OF BETA-GLUCAN IN FOOD INDUSTRY
    • 4.2.3. DECREASING PRICES OF MAJOR RAW MATERIAL SOURCES
  • 4.3. RESTRAINTS
    • 4.3.1. VARIOUS SIDE EFFECTS OF CONSUMING BETA GLUCAN
    • 4.3.2. INCONSISTENCY IN REGULATORY NORMS
  • 4.4. OPPORTUNITIES
    • 4.4.1. UNEXPLOITED BETA GLUCAN APPLICATIONS IN COSMETIC AND MEDICINE SECTOR
  • 4.5. CHALLENGES
    • 4.5.1. INCREASE IN THE COST OF BETA-GLUCAN EXTRACTION PROCESS

5. MARKET BY SOURCE

  • 5.1. BACTERIA
  • 5.2. FUNGUS
  • 5.3. YEAST
  • 5.4. CEREAL
  • 5.5. ALGAE

6. MARKET BY END-USERS

  • 6.1. FOOD AND BEVERAGES
  • 6.2. PERSONAL CARE
  • 6.3. PHARMACEUTICALS
  • 6.4. ANIMAL FEED

7. MARKET BY CATEGORY

  • 7.1. INSOLUBLE BETA GLUCAN
  • 7.2. SOLUBLE BETA GLUCAN

8. KEY ANALYTICS

  • 8.1. PORTER'S 5 FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. KEY BUYING CRITERIA
    • 8.2.1. COST
    • 8.2.2. NUTRITIONAL CONTENT
    • 8.2.3. SOURCE
    • 8.2.4. APPLICATIONS
  • 8.3. VALUE CHAIN ANALYSIS
    • 8.3.1. RAW MATERIAL SUPPLIERS
    • 8.3.2. MANUFACTURING
    • 8.3.3. DISTRIBUTORS/RETAILERS
    • 8.3.4. END-USERS
  • 8.4. KEY TRENDS
    • 8.4.1. RISING PREVALENCE OF DIABETES
    • 8.4.2. INVESTMENTS IN BETA GLUCAN
  • 8.5. INVESTMENT OUTLOOK
    • 8.5.1. END-USERS OUTLOOK
  • 8.6. VENDOR LANDSCAPE
  • 8.7. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. CHINA
  • 9.2. INDIA
  • 9.3. JAPAN
  • 9.4. SOUTH KOREA
  • 9.5. AUSTRALIA
  • 9.6. REST OF ASIA PACIFIC

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
    • 10.1.1. CARGILL INC (US)
    • 10.1.2. TATE & LYLE (UK)
    • 10.1.3. KERRY GROUP PLC (ISRAEL)
    • 10.1.4. OHLY (GERMANY)
    • 10.1.5. KONINKLIJKE DSM N.V. (NETHERLANDS)
  • 10.2. COMPANY PROFILES
    • 10.2.1. ALLTECH BIOTECHNOLOGY
      • 10.2.1.1. OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
      • 10.2.1.4. STRATEGIC ANALYSIS
    • 10.2.2. CARGILL INC
      • 10.2.2.1. OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC ANALYSIS
    • 10.2.3. CHR. HANSEN A/S
      • 10.2.3.1. OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC ANALYSIS
    • 10.2.4. GARUDA INTERNATIONAL INC
      • 10.2.4.1. OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
      • 10.2.4.4. STRATEGIC ANALYSIS
    • 10.2.5. KEMIN INDUSTRIES
      • 10.2.5.1. OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
      • 10.2.5.3. STRATEGIC INITIATIVES
      • 10.2.5.4. SCOT ANALYSIS
      • 10.2.5.5. STRATEGIC ANALYSIS
    • 10.2.6. SPECIALTY BIOTECH LTD
      • 10.2.6.1. OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC ANALYSIS
    • 10.2.7. MILLIPORESIGMA (MERCK)
      • 10.2.7.1. OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. SCOT ANALYSIS
      • 10.2.7.4. STRATEGIC ANALYSIS
    • 10.2.8. OHLY
      • 10.2.8.1. OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. STRATEGIC INITIATIVES
      • 10.2.8.4. SCOT ANALYSIS
      • 10.2.8.5. STRATEGIC ANALYSIS
    • 10.2.9. TATE & LYLE PLC
      • 10.2.9.1. OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
      • 10.2.9.4. SCOT ANALYSIS
      • 10.2.9.5. STRATEGIC ANALYSIS
    • 10.2.10. SUPER BETA GLUCAN
      • 10.2.10.1. OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC ANALYSIS
    • 10.2.11. KONINKLIJKE DSM N.V.
      • 10.2.11.1. OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC ANALYSIS
    • 10.2.12. FRUTAROM
      • 10.2.12.1. OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC ANALYSIS
    • 10.2.13. KERRY GROUP PLC
      • 10.2.13.1. OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. STRATEGIC ANALYSIS
      • 10.2.13.4. SCOT ANALYSIS
      • 10.2.13.5. STRATEGIC ANALYSIS
    • 10.2.14. LESAFFRE HUMAN CARE
      • 10.2.14.1. OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. SCOT ANALYSIS
      • 10.2.14.4. STRATEGIC ANALYSIS
    • 10.2.15. PHARMACON ASA
      • 10.2.15.1. OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. STRATEGIC INITIATIVES
      • 10.2.15.4. SCOT ANALYSIS
      • 10.2.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC BETA GLUCAN MARKET BY COUNTRY 2018-2026 ($ MILLION)
  • TABLE 2 APPLICATIONS OF DIFFERENT BETA GLUCAN IN FOOD PRODUCTION
  • TABLE 3 ASIA PACIFIC BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • TABLE 4 ASIA PACIFIC BETA GLUCAN MARKET BY END-USERS 2018-2026 ($ MILLION)
  • TABLE 5 ASIA PACIFIC BETA GLUCAN MARKET BY CATEGORY 2018-2026 ($ MILLION)
  • TABLE 6 INVESTMENTS IN BETA GLUCAN
  • TABLE 7 ASIA PACIFIC BETA GLUCAN MARKET BY COUNTRY 2018-2026 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • FIGURE 2 ASIA PACIFIC SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 3 ASIA PACIFIC CEREALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 4 EVOLUTION OF BETA-GLUCAN MARKET
  • FIGURE 5 HEALTHCARE SPENDING PER CAPITA IN 2015 AND 2016
  • FIGURE 6 COMMODITY PRICE INDEX OF WHEAT CROPS
  • FIGURE 7 ASIA PACIFIC COSMETICS PRODUCTS MARKET 2015 ($ BILLION)
  • FIGURE 8 ASIA PACIFIC BACTERIA MARKET 2018-2026 ($ MILLION)
  • FIGURE 9 ASIA PACIFIC FUNGUS MARKET 2018-2026 ($ MILLION)
  • FIGURE 10 ASIA PACIFIC YEAST MARKET 2018-2026 ($ MILLION)
  • FIGURE 11 ASIA PACIFIC CEREAL MARKET 2018-2026 ($ MILLION)
  • FIGURE 12 ASIA PACIFIC ALGAE MARKET 2018-2026 ($ MILLION)
  • FIGURE 13 ASIA PACIFIC FOOD AND BEVERAGES MARKET 2018-2026 ($ MILLION)
  • FIGURE 14 ASIA PACIFIC PERSONAL CARE MARKET 2018-2026 ($ MILLION)
  • FIGURE 15 ASIA PACIFIC PHARMACEUTICALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 16 ASIA PACIFIC ANIMAL FEED MARKET 2018-2026 ($ MILLION)
  • FIGURE 17 ASIA PACIFIC INSOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 18 ASIA PACIFIC SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 19 TOP 10 COUNTRIES WITH NUMBER OF PEOPLE LIVING WITH DIABETES IN MILLION (2015)
  • FIGURE 20 PERCENTAGE INCREMENT OF DIABETES ACROSS REGIONS (2015 TO 2040)
  • FIGURE 21 INVESTMENT PROPOSITION FOR ASIA PACIFIC BETA GLUCAN MARKET BY END-USERS - 2017
  • FIGURE 22 CHINA BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 23 INDIA BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 24 JAPAN BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 25 SOUTH KOREA BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 26 AUSTRALIA BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 27 REST OF APAC BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 28 MARKET SHARE ANALYSIS OF TOP COMPANIES IN ASIA PACIFIC BETA GLUCAN MARKET - 2017 (%)
Back to Top